PMID- 21484798
OWN - NLM
STAT- MEDLINE
DCOM- 20120210
LR  - 20191210
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 130
IP  - 5
DP  - 2012 Mar 1
TI  - Isolation of disseminated neuroblastoma cells from bone marrow aspirates for 
      pretreatment risk assessment by array comparative genomic hybridization.
PG  - 1098-108
LID - 10.1002/ijc.26133 [doi]
AB  - In neuroblastoma, tumor biopsies are used for prognostic evaluation and risk 
      assessment by molecular genetic analyses such as fluorescence in situ 
      hybridization (FISH) and array comparative genomic hybridization (array CGH). 
      Analysis of primary tumors by array CGH can be hampered by the lack of sufficient 
      tumor cells due to small biopsy size or availability of invaded bone marrow only. 
      Given the importance of accurate assessment of genetic alterations in the 
      diagnostic work-up of patients with neuroblastoma, we evaluated the possibility 
      to analyze bone marrow metastases in patients with disseminated disease. 
      Disseminated neuroblastoma cells were isolated from bone marrow aspirates by 
      using either laser capture microdissection (LCM) or magnetic activated cell 
      sorting (MACS). The array CGH profiles of these isolated metastases were compared 
      to array CGH profiles and/or FISH data of the corresponding primary tumor. Here, 
      we show that the major recurrent DNA copy number alterations detected in primary 
      neuroblastoma tumors (i.e., 1p, 3p and 11q deletion, 17q gain and MYCN 
      amplification) can be detected, with high sensitivity and specificity, in the 
      disseminated neuroblastoma cells isolated from the bone marrow aspirates, using 
      an array platform with high coverage for these regions. Moreover, we demonstrate 
      that for archived material, for example, for retrospective studies, LCM is the 
      method of choice, while for fresh bone marrow aspirates, acquired at the time of 
      diagnosis, MACS is superior.
CI  - Copyright (c) 2011 UICC.
FAU - Vandewoestyne, Mado
AU  - Vandewoestyne M
AD  - Faculty of Pharmaceutical Sciences, Laboratory of Pharmaceutical Biotechnology, 
      Ghent University, Ghent, Belgium. mado.vandewoestyne@ugent.be.
FAU - Kumps, Candy
AU  - Kumps C
FAU - Swerts, Katrien
AU  - Swerts K
FAU - Menten, Bjorn
AU  - Menten B
FAU - Lammens, Tim
AU  - Lammens T
FAU - Philippe, Jan
AU  - Philippe J
FAU - De Preter, Katleen
AU  - De Preter K
FAU - Laureys, Genevieve
AU  - Laureys G
FAU - Van Roy, Nadine
AU  - Van Roy N
FAU - Speleman, Frank
AU  - Speleman F
FAU - Deforce, Dieter
AU  - Deforce D
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110609
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
SB  - IM
MH  - Bone Marrow/*pathology
MH  - Bone Marrow Neoplasms/diagnosis/*secondary
MH  - *Comparative Genomic Hybridization
MH  - Flow Cytometry
MH  - Humans
MH  - Laser Capture Microdissection
MH  - Neuroblastoma/diagnosis/*pathology
EDAT- 2011/04/13 06:00
MHDA- 2012/02/11 06:00
CRDT- 2011/04/13 06:00
PHST- 2010/10/14 00:00 [received]
PHST- 2011/03/15 00:00 [accepted]
PHST- 2011/04/13 06:00 [entrez]
PHST- 2011/04/13 06:00 [pubmed]
PHST- 2012/02/11 06:00 [medline]
AID - 10.1002/ijc.26133 [doi]
PST - ppublish
SO  - Int J Cancer. 2012 Mar 1;130(5):1098-108. doi: 10.1002/ijc.26133. Epub 2011 Jun 
      9.